These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 28039712

  • 1. EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer.
    Zhang F, Zhang H, Wang F.
    J BUON; 2016; 21(6):1482-1490. PubMed ID: 28039712
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
    OuYang Y, Zou W, Peng L, Yang Z, Tang Q, Chen M, Jia S, Zhang H, Lan Z, Zheng P, Zhu W.
    Eur J Med Chem; 2018 Jun 25; 154():29-43. PubMed ID: 29775935
    [Abstract] [Full Text] [Related]

  • 3. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X, Lv Y, Liu P, Li Z, Hu L, Zeng C, Yang L.
    Bioorg Med Chem Lett; 2016 Mar 15; 26(6):1571-1575. PubMed ID: 26879314
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J, Wan S, Wang G, Zhang T, Li Z, Tian Y, Yu Y, Wu X, Zhang J.
    Eur J Med Chem; 2016 Aug 08; 118():276-89. PubMed ID: 27132165
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
    Tu Y, Wang C, Xu S, Lan Z, Li W, Han J, Zhou Y, Zheng P, Zhu W.
    Bioorg Med Chem; 2017 Jun 15; 25(12):3148-3157. PubMed ID: 28428040
    [Abstract] [Full Text] [Related]

  • 6. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J, Ren H, Zhao M, Chong Y, Zhao W, He Y, Zhao Y, Zhang H, Qi C.
    Eur J Med Chem; 2017 Sep 29; 138():669-688. PubMed ID: 28711702
    [Abstract] [Full Text] [Related]

  • 7. Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors.
    Tu Y, OuYang Y, Xu S, Zhu Y, Li G, Sun C, Zheng P, Zhu W.
    Bioorg Med Chem; 2016 Apr 01; 24(7):1495-503. PubMed ID: 26906472
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
    Mowafy S, Farag NA, Abouzid KA.
    Eur J Med Chem; 2013 Mar 01; 61():132-45. PubMed ID: 23142066
    [Abstract] [Full Text] [Related]

  • 11. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
    Hou W, Ren Y, Zhang Z, Sun H, Ma Y, Yan B.
    Bioorg Med Chem; 2018 May 01; 26(8):1740-1750. PubMed ID: 29523467
    [Abstract] [Full Text] [Related]

  • 12. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors.
    Alsaid MS, Al-Mishari AA, Soliman AM, Ragab FA, Ghorab MM.
    Eur J Med Chem; 2017 Dec 01; 141():84-91. PubMed ID: 29028534
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
    Zhang X, Peng T, Ji X, Li J, Tong L, Li Z, Yang W, Xu Y, Li M, Ding J, Jiang H, Xie H, Liu H.
    Bioorg Med Chem; 2013 Dec 15; 21(24):7988-98. PubMed ID: 24183742
    [Abstract] [Full Text] [Related]

  • 14. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
    Barbosa ML, Lima LM, Tesch R, Sant'Anna CM, Totzke F, Kubbutat MH, Schächtele C, Laufer SA, Barreiro EJ.
    Eur J Med Chem; 2014 Jan 15; 71():1-14. PubMed ID: 24269511
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD, Fang F, Li JR, Du QR, Sun J, Gong HB, Zhu HL.
    Bioorg Med Chem Lett; 2012 Sep 15; 22(18):5870-5. PubMed ID: 22901387
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity.
    Ahmed MF, Magdy N.
    Anticancer Agents Med Chem; 2017 Sep 15; 17(6):832-838. PubMed ID: 27671305
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.